Biotech (688177.SH): BAT5906 approved for drug clinical trials

Zhitongcaijing · 08/01/2025 08:25

Zhitong Finance App News, Biotech (688177.SH) announced that the company recently received the approval and issuance of the “Drug Clinical Trial Approval Notice” for the recombinant anti-VEGF humanized monoclonal antibody injection (BAT5906) under development to add macular edema (CRVO-ME) due to central retinal vein occlusion (CRVO-ME) and choroidal neovascularization (pmCNV) of pathological myopia.

According to the announcement, BAT5906 is an innovative recombinant humanized monoclonal antibody independently developed and produced by Baiaotai. It is an IgG1 full-length antibody with a molecular weight of 149 kDa. It can bind specifically with human VEGF-A165 and inhibit angiogenesis. In vitro angiogenesis models, BAT5906 can block VEGF from binding to its corresponding receptors and inhibit endothelial cell proliferation and angiogenesis. In animal experiments, BAT5906 has a longer serum half-life than ranibizumab, which is structured as a Fab fragment, and may support longer clinical injection cycles. In terms of drug safety, it does not trigger antibody-dependent cell-mediated cytotoxicity (ADCC), so systemic adverse effects are small, and clinical application may be safer.